Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 9

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 9
---
 of NLS and its shareholders, has approved the Merger Agreement, the Merger, the issuance of the NLS Common Shares to Kadimastem’s shareholders pursuant to the terms of the Merger Agreement, the increase in share capital of the Company by way of an ordinary capital increase, the reinstatement of the capital band and the approval of the upper and the lower limit of the capital band in article 3a paragraph 1 of the Articles, the approval of the conditional share capital for employees and advisors (article 3b), the approval of the conditional share capital for shareholders’ options (article 3c), the change of the Company’s name to NewcelX Ltd. and related amendment to article 1 of the Articles, the election of a new Chairman and members of the NLS Board, the election of members of the Compensation, Nomination and Governance Committee, the approval of the new maximum aggregate amount of fixed compensation of the NLS Board, the approval of the CVR Agreement and the conversion of outstanding options and RSUs of Kadimastem, and the other actions contemplated by the Merger Agreement, and has determined to recommend that the NLS shareholders vote to approve each of the proposals set forth in this proxy statement/prospectus. Accordingly, the NLS Board unanimously recommends that the NLS shareholders vote FOR each of the Proposals Nos. 1 through 13 described above.

Your vote is very important, regardless of the number of shares you own.We cannot complete the Merger unless the shareholders of NLS approve the Merger -relatedproposals and the other transactions contemplated by the Merger Agreement. Whether or not you expect to attend the NLS Meeting in person, please complete, date, sign and promptly return the accompanying proxy card in the enclosed postage paid envelope to ensure that your shares will be represented and voted at the NLS Meeting. More information about NLS, Kadimastem and the proposed transactions is contained in this proxy statement/prospectus. NLS urges you to read this proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “RISK FACTORS” BEGINNING ON PAGE 25. NLS is excited about the opportunities the Merger brings to its shareholders, and thanks you for your consideration and continued support.

| Sincerely,                         |
| /s/ Ronald Hafner                  |
| Ronald Hafner                      |
| Chairman of the Board of Directors |

None of the